14
May/June 2011
Avantor Performance Materials to Acquire POCH S.A. from Kulczyk Holding
Figure 3: Typical HILIC chromatogram for Dextran-1 150 mg/mL Solution for Injection
AvantorT Performance Materials (USA) announces a definitive agreement to acquire POCH S.A. from Kulczyk. Completion of the sale is dependent on obtaining the necessary clearance from the Polish competition authority, and is subject to customary closing conditions. Terms of the deal were not disclosed.
Size Exclusion Determination `
Glucose Unit (i)
1 2 3 4 5 6 7 8 9
10 11 12 13 14 15
Mi
180 342 504 666 828 990
1152 1314 1476 1638 1800 1962 2124 2286 2448
Mw=∑(Wi * Mi)
<3 glucose units,% >9 glucose units, %
%Area Wi * Mi 0.25 3.59
0.5
13.15 17.03 16.14 13.52 10.56 7.96 5.91 4.23 3.03 2.11 1.54 0.99
12.3 66.3
113.4 133.7 133.8 121.6 104.6 87.2 69.2 54.5 41.5 32.7 22.7
993.8 3.8
11.9 Table 4: Comparison of molecular weight fractions for Dextran-1 by SEC and HILIC HILIC Determination
%Area Wi * Mi 0.35 3.78
0.6
12.57 15.12 14.28 18.67 10.81 8.22 5.84 4.08 2.67 1.71 1.04 0.58 0.28
12.9 63.4
100.7 118.2 184.8 124.5 108.0 86.2 66.9 48.0 33.5 22.1 13.3 6.8
990.0 4.1
10.1
Avantor Performance Materials, formerly Mallinckrodt Baker, manufactures and markets high-performance chemistries and materials around the world under several well respected brand names, including the
J.T.BakerR, MacronT, RankemT and DiagnovaT brands. Avantor products are used in a wide range of industries including biotechnology and pharmaceutical production; and in research, academic and quality control laboratories. The company is owned by an affiliate of private equity firm New Mountain Capital.
Based in Poland, POCH S.A. manufactures products designed for use in classic and instrumental analysis, filtration and microbiology. POCH S.A. also sells laboratory equipment and laboratory glass. Moreover, POCH S.A. also manufactures solvents for liquid and gas chromatography and spectroscopy as well as anhydrous solvents. Its markets include pharmaceuticals; food and feed; chemical and petrochemical; environmental protection and research and analytical chemistry.
References 1. European Pharmacopoeia 7.1 – Dextran-1 for Injection Monograph 2. Moncrieff J. A., Darin J. C., Canizaro P
. C., Sawer R. B. Annals of Surgery (1963), 158(4), 553
3. Wang D. Y., Forslund C., Persson U., Wilholm B.E., Pharmacoepidemiol and Drug Safety (1998), 7(4), 269 4. European Pharmacopoeia 7.1 – Dextran-1 for Injection Monograph 5. Grumach E. S., Wagrowski-Diehl D. M., Mazzeo J. R., Alden B., Iraneta P 6. Phenomenex Luna HILIC Method Development Guidelines
"The transaction is part of Avantor’s strategy to strengthen its presence in the global market by growing both organically and through acquisition, expanding into new markets and geographies," said Avantor President and Chief Executive Officer Jean-Marc Gilson. "POCH fits this strategy because of its established and expansive manufacturing presence and distribution channel in Poland and Eastern Europe."
. C., LCGC North America (2004), 22(10), 1010
For more information, visit
www.avantorperformancematerials.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52